Sterling Pharma Solutions acquired by GHO Capital

14 March 2019
2019_pharma_pill_api_production_big

A majority equity stake in British active pharmaceutical ingredients (API) contract development and manufacturing organization Sterling Pharma Solutions has been acquired by GHO Capital following its impressive growth. The acquisition, the value of which was not disclosed, will pave the way for further growth in 2019 and the coming years.

Headquartered in Newcastle upon Tyne, UK, Sterling is a leading provider of complex and difficult to manufacture API development and manufacturing, with a reputation for world class quality standards. This is reflected in Sterling’s long-term relationships with blue-chip pharmaceutical and animal health clients, as well as a strong track record with global regulators including the Food and Drug Administration and European Medicine Agency.

Outsourced small molecule API development and manufacturing is growing steadily at around 7% per annum. This is overlaid with a long-term trend towards increasing molecule complexity, driving higher market growth rates in complex chemistry, where Sterling is an industry leader in Europe.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics